产品名称:Anti-H_GDF15 hIgG4 Antibody(CTL-002) 目录价:询价 规格货号 GM-71274AB-10 10 μg GM-71274AB-100 100 μg GM-71274AB-1000 1mg 产品简介 Species ReactivityHuman CloneCTL-002 Source/IsotypeMonoclonal Human IgG1/κ ApplicationFlow Cytometry ...
In preclinical models CTL-002 demonstrated potent effector T cell shifting into tumor tissue by neutralizing GDF-15 and enhancing response to checkpoint inhibitor therapy. Methods: This is a phase 1, first-in-human (FIH), two-part, open-label clinical trial of intravenous (IV) administration of...
ctl cmd pkg LICENSE LICENSES go.mod go.sum main.go webhook deploy design docs gcb hack internal logo make pkg test tools .bazelignore .bazelrc .gitignore .krew.yaml .trivyignore CODE_OF_CONDUCT.md CONTRIBUTING.md LICENSE LICENSES Makefile ...
729MO Final results of the first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in combination with nivolumab in subjects with solid tumors relapsed/refractory to prior anti-PD1/PD-L1 treatmentdoi:10.1016/j.annonc.2022.07.855I. Melero...
Here we report initial results of the phase 2a part of the GDF-15 neutralizing antibody visugromab (CTL-002) in combination with nivolumab. Methods: At cut-off date (06-Feb-2023), a total of 79 pts with advanced/metastatic solid tumors have been enrolled and were treated with visugromab...